The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Glucocorticoid Found to Increase Bone Mineral Density in Mouse Study

Glucocorticoid Found to Increase Bone Mineral Density in Mouse Study

December 19, 2014 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Many physicians associate glucocorticoids with osteoporosis. The association is confounded, however, by the fact that studies on the subject have frequently included postmenopausal women who are at an already increased risk for osteoporosis. That said, in vitro studies have specifically demonstrated that glucocorticoids directly affect bone cells and decrease bone formation, lending credence to the belief that glucocorticoids are bad for bone. The understanding of the relationship between glucocorticoids and bone becomes more puzzling, however, by the publication of a new paper that reports treatment with the glucocorticoid dexamethasone (dex) may actually increase trabecular bone density.

You Might Also Like
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Bone Mineral Density Most Important Determinant of Fracture Risk
Also By This Author
  • IgG from Patients with Autoimmune Disease Activates Neutrophils

Louise Grahnemo, PhD, postdoctoral fellow at the University of Gothenburg in Sweden and colleagues published the results of their study on female mice in the Journal of Endocrinology.1 The investigators designed their research to determine the mechanism behind the effects of glucocorticoids on bone, both in general and specifically during menopause.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

They focused their efforts on the role that lymphocytes play in the mix. They highlighted these cells because of their documented role in both postmenopausal and arthritis-induced osteoporosis. Moreover, the investigators were intrigued by the knowledge that glucocorticoids target lymphocytes.

Grahnemo et al report that treatment with the glucocorticoid dex, but not the nonsteroidal antiinflammatory drug carprofen (carp), increased trabecular bone mineral density (BMD) in female C57BL/6 or SCID mice as compared with control and carp-treated mice. In addition, dex-treated mice had markedly decreased numbers of splenic T and B cells, and lower levels of serum bone turnover markers, than carp-treated mice.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The team next investigated the role of estrogen in the relationship between glucocorticoids and bone. They used ovariectomized (ovx) mice as a model for postmenopausal osteoporosis. Ovx induces a decrease in bone volume fraction, trabecular thickness and trabecular number. The investigators sham-operated or ovariectomized C57BL/6 mice and, two weeks later, treated the recovering mice with dex, carp or a vehicle control. Treatment was continued for 2.5 weeks. The mice were then sacrificed and their femurs phenotyped using high-resolution micro-computed tomography and peripheral quantitative computed tomography. T and B cell populations in the spleen and bone marrow were quantified by flow cytometry and the serum was analyzed for markers of bone turnover. The investigators found that treatment with dex, but not carp, increased trabecular BMD in ovx C57BL/6 mice. They also found that the bone effects (cortical content and thickness) were dex-dose dependent.

While dex and carp are both anti-inflammatory agents, dex has lymphocyte-suppressive effects that carp does not have. As expected, treatment with dex, but not carp, decreased lymphocyte count. Moreover, dex was unable to increase BMD in ovx mice lacking functional T and B cells, suggesting that lymphocytes are critical for the effect of dex on bone.

Pages: 1 2 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Research Reviews Tagged With: bone, Glucocorticoids, Osteoporosis, Research

You Might Also Like:
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Bone Mineral Density Most Important Determinant of Fracture Risk
  • Glucocorticoid-Induced Osteoporosis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.